Safe Fertility Group Public Company LimitedSET: SAFE🇹🇭 TH

Internal Control · 2025

Internal Control — Board Opinion

Summary of the Board's Opinion on Internal Control

The Board of Directors has considered and conducted an assessment of the adequacy of the internal control system of the Group. This assessment was based on the internal audit reports, the recommendations of the external auditor, and additional inquiries made with the management. The Board is of the opinion that the Company’s internal control system is adequate and appropriate for the size and nature of the Company’s business operations. It also complies with relevant laws and regulations and aligns with the principles of Good Corporate Governance.

In addition, the Company has established management practices that promote awareness among employees regarding the importance of internal control. The Company has also ensured that sufficient personnel are in place to effectively implement the internal control system, covering all five key components under the framework of the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Furthermore, the Company has clearly defined duties and responsibilities and has established written rules, regulations, policies, and appropriate authorization levels for operational approvals.

With respect to the internal control systems of the Company’s two subsidiaries, the Company requires these subsidiaries to implement internal control systems in line with the Company’s internal control guidelines. In addition, the Company has assigned internal audit personnel to conduct operational audits of these subsidiaries. In 2025, it was found that all subsidiaries had established adequate internal control systems across all five components, similar to those of the Company.

Adequacy & Appropriateness of the Internal Control System

Internal Control Framework Used

FrameworkDetail
The Committee of Sponsoring Organizations of the Treadway Commission (COSO)

The assessment of the internal control system in accordance with the framework of the Committee of Sponsoring Organizations of the Treadway Commission (COSO) consists of the following five components:

  1. Control Environment

  2. Risk Assessment

  3. Control Activities

  4. Information and Communication

  5. Monitoring Activities

Internal Control Deficiencies

Number of Deficiencies

MetricCurrent YearPrevious YearTwo Years Ago
Total number of internal control system deficiencies (cases)000

Audit Committee & Auditor Observations

Audit Committee's Opinion Differs from the Board's

No

Auditor Has Observations on Internal Control

No

Opinion on the Head of Internal Audit

Head of Internal Audit

3160

Audit Committee's Opinion on the Head of Internal Audit

The Audit Committee considered the qualifications of Dharmniti Internal Audit Company Limited, as the internal auditor of the Group, and has appointed Miss Somjaree Khaewkhomdee as head of the internal audit. After consideration, it was determined that she possesses the appropriate education, experience, and training necessary to fulfill the role of internal auditor for the Company, as well as the independence required to conduct audits and assess the adequacy of the internal control system and compliance with the Company’s policies. The internal auditor has coordinated with personnel of all departments of the Company, followed up on improvements of the internal control system in accordance with the recommendations of the internal audit, and prepared reports on the assessment and audit results of the company’s internal control system. These reports are continuously presented directly to the Audit Committee. (details about the qualifications of the head of internal audit are provided in Attachment 3, “Details about the Head of Internal Audit of the Company”).

Appointment, Discharge & Transfer of the Head of Internal Audit

Requires Audit Committee Approval

Yes

Description

According to the scope of authority, duties, and responsibilities of the Audit Committee, the Audit Committee shares authority with management in evaluating the performance, determining the merit, and deciding on the removal, transfer, or dismissal of the head of the internal audit department for the group of companies.

Related Party Transactions

Has Related Party Transactions

Yes

Counterparties & Transactions

Monetary Unit

1

Counterparties with Potential Conflicts

NamePerson / Juristic PersonType of BusinessNature of RelationshipAs of Date (YYYY-MM-DD)
Mr. Wiwat QuangkananurugPerson

Physician / Major Shareholder / Chief Executive Officer / Chief Medical Officer / Director

2025-12-31T00:00
Next Generation Genomic Company LimitedJuristic PersonProviding embryo genetic diagnosis services and genetic laboratories

Subsidiary

2025-12-31T00:00
Safe Wellness Company LimitedJuristic PersonProviding aesthetic and wellness services

Subsidiary

2025-12-31T00:00
Thisarathorn Company LimitedJuristic PersonDistribution of dietary supplements, beauty products, and health products.

Common Shareholder with Subsidiary

2025-12-31T00:00

Transactions by Counterparty

Transactions
17469870.3 · Necessity: These medical fees are charged according to the rates set by the company, which are the standard professional fees for senior physicians, paid equally to all senior physicians under the service package provided. The terms are the same as for other senior physicians who are not related parties of the company. The payment of these medical fees is the net amount after deducting facility costs at a fair rate, in line with the company's policy on medical fee payments, which has been communicated to all physicians. · Description: The Company has paid professional medical fees to Mr. Wiwat Quangkananurug in his capacity as the company's senior physician. · As of yesteryear: 24420743.1 · Nature of transaction: Medical Professional Fee · Audit committee opinion: Such a related party transaction is reasonable and is a transaction of a general nature with an agreement that is a requirement in the same way as entering into a transaction with other parties in general, and the transaction does not create a transfer of interest between the Company or its subsidiaries. · As of year before yesteryear: 23642165.2
43913549.0 · Necessity: The service fees for such transactions are based on market prices or comparable rates offered by external service providers, in accordance with the standard commercial transaction. · Description: Next Generation Genomics Co., Ltd. provides genetic testing services for embryos and fetuses to the Company. · As of yesteryear: 51581357.0 · Nature of transaction: Genetic testing service fee · Audit committee opinion: Such related party transaction is reasonable and conducted in the general transaction. The pricing is determined on fair commercial terms, with reference to market prices or comparable rates offered by external service providers, and there are no conditions that would result in any transfer of benefits between the Company and its subsidiaries. · As of year before yesteryear: 55378570.0 · 168009.0 · Necessity: The Company determines purchase and selling prices with reference to market prices or comparable prices offered by external suppliers, under fair commercial terms and in accordance with the Company’s procurement policies and procedures. · Description: Next Generation Genomics Co., Ltd. sells laboratory reagents and medical supplies to the Company. · As of yesteryear: 4529.0 · Nature of transaction: Expenses of laboratory reagents and medical supplies · Audit committee opinion: Such related party transaction is reasonable and conducted in the general transaction. The pricing is determined on fair commercial terms, with reference to market prices or comparable rates offered by external service providers, and there are no conditions that would result in any transfer of benefits between the Company and its subsidiaries. · As of year before yesteryear: 9852.0 · 176924.0 · Necessity: The Company determines purchase and selling prices with reference to market prices or comparable prices offered by external suppliers, under fair commercial terms. · Description: The Company sells medicines and medical supplies to Next Generation Genomics Co., Ltd. · As of yesteryear: 188190.0 · Nature of transaction: Revenue from sales · Audit committee opinion: Such related party transaction is reasonable and conducted in the general transaction. The pricing is determined on fair commercial terms, with reference to market prices or comparable rates offered by external service providers, and there are no conditions that would result in any transfer of benefits between the Company and its subsidiaries. · As of year before yesteryear: 335208.0
70316.0 · Necessity: The pricing for such transactions are based on market prices or comparable rates offered by external service providers, in accordance with the standard commercial transaction. · Description: The Company sells medicines and medical supplies to Safe Wellness Co., Ltd. · As of yesteryear: 23776.0 · Nature of transaction: Revenue from sales · Audit committee opinion: Such related party transaction is reasonable and conducted in the general transaction. The pricing is determined on fair commercial terms, with reference to market prices or comparable rates offered by external service providers, and there are no conditions that would result in any transfer of benefits between the Company and its subsidiaries. · As of year before yesteryear: 22835.0 · 7850.0 · Necessity: The service fees for such transactions are determined with reference to market prices or comparable rates charged to the Company’s customers, in accordance with the standard commercial transaction. · Description: The Company provides patient room services to customers of Safe Wellness Co., Ltd. · As of yesteryear: 0.0 · Nature of transaction: Revenue from services · Audit committee opinion: Such related party transaction is reasonable and conducted in the general transaction. The pricing is determined on fair commercial terms, with reference to market prices or comparable rates offered by external service providers, and there are no conditions that would result in any transfer of benefits between the Company and its subsidiaries. · As of year before yesteryear: 0.0 · 0.0 · Necessity: The Company determines purchase and selling prices with reference to market prices or comparable prices offered by external suppliers, under fair commercial terms and in accordance with the Company’s procurement policies and procedures. · Description: Safe Wellness Co., Ltd. sells medicines and medical supplies to the Company. · As of yesteryear: 80250.0 · Nature of transaction: Expenses for medicines and medical supplies · Audit committee opinion: Such related party transaction is reasonable and conducted in the general transaction. The pricing is determined on fair commercial terms, with reference to market prices or comparable rates offered by external service providers, and there are no conditions that would result in any transfer of benefits between the Company and its subsidiaries. · As of year before yesteryear: 0.0
1200000.0 · Necessity: The transaction of consulting fees is necessary for the Company’s business operations, as it supports strategic planning, business development, and enhances operational efficiency across various functions by leveraging the specialized expertise of the consultant. · Description: Safe Wellness Co., Ltd., a subsidiary of the Company, has engaged Thisarathorn Co., Ltd. as a marketing consultant. · As of yesteryear: 800000.0 · Nature of transaction: Consulting fee · Audit committee opinion: The transaction is considered reasonable. The consulting fee is appropriate when compared to those charged by experts providing a similar service and is in line with normal commercial terms. Therefore, the transaction is deemed to be beneficial to the Company and its shareholders as a whole. · As of year before yesteryear: 0.0
999633.85 · Necessity: Commission fee for customer referrals is necessary for the Company’s business operations, as they serve as a marketing tool to expand the customer base and increase access to target customer segments by leveraging the referrer’s network and expertise. · Description: Safe Wellness Co., Ltd., a subsidiary of the Company, has paid commission fees to Thisarathorn Co., Ltd. for referring customers to use its services. · As of yesteryear: 721778.45 · Nature of transaction: Commission fee · Audit committee opinion: The transaction is necessary and reasonable for the Company’s business operations. The terms and remuneration are in line with normal business practices, are transparent, and do not give rise to any inappropriate conflicts of interest. Furthermore, the transaction is in the best interests of the Company and its shareholders as a whole.

Policy & Future Trends

Policy, Measures & Approval Process

In conducting related party transactions of the Company and its subsidiaries, the Company will comply with the Securities and Exchange Act B.E. 2535 (including amendments), regulations, announcements, orders, and guidelines from the Stock Exchange of Thailand and/or the Securities and Exchange Commission and/or the Capital Market Supervisory Board, as well as requirements for disclosure of related party transactions in the notes to the financial statements, which have been audited and/or reviewed by the Company's and its subsidiaries' auditors. These transactions will also be reported in the annual information form/annual report (Form 56-1 One Report). The approval measures and procedures for related party transactions are as follows:

  1. The Board of Directors will establish procedures for considering and approving related party transactions in accordance with the Company’s and subsidiaries' operating procedures. These will be governed by good ethical standards and reviewed by the Audit Committee, focusing on the interests of the Company and shareholders. The Company will ensure compliance with the regulations, announcements, orders, and guidelines of the Stock Exchange of Thailand, the Securities and Exchange Commission, and/or the Capital Market Supervisory Board. It will also consider the accuracy and completeness of the disclosure of related party transactions to the public.

  2. The consideration for approving transactions will take into account the appropriateness of the price and the reasonableness of the transaction. This includes ensuring that terms are in line with normal business operations in the industry and/or are compared to external market prices and/or are conducted under the same terms and conditions as those with external parties. It must also be demonstrable that the transaction was carried out with fair and reasonable terms.

  3. When considering related party transactions, directors who have a vested interest and/or directors who are related parties will not attend the meeting and will not have the right to vote on approving such transactions. This ensures that the transaction does not involve shifting or transferring benefits between the company and its stakeholders but is conducted with the utmost consideration for the interests of the Company and its shareholders.

  4. The Company will only conduct related party transactions once they have been approved in accordance with the criteria set by the Stock Exchange of Thailand, the Securities and Exchange Commission, and/or the Capital Market Supervisory Board, unless the transaction is a commercial agreement that would normally be made with an unrelated counterparty in similar circumstances, with bargaining power free from influence due to the director's position. Such transactions must be approved by the Board of Directors or align with previously approved principles.

  5. In certain cases, the company may appoint experts, such as independent advisors, auditors, or asset appraisers, to provide opinions on related party transactions for the consideration of the Audit Committee, the Board of Directors, and/or the shareholders' meeting (as applicable).

  6. The Company will prepare a summary report of related party transactions to be presented at each quarterly meeting of the Audit Committee and the Board of Directors, in accordance with the Securities and Exchange Act and related regulations, announcements, orders, and requirements from the Securities and Exchange Commission and the Stock Exchange of Thailand.

The Company’s the Internal Audit Office will review related party transactions according to the audit plan, with reports to the Audit Committee. There will be control measures to ensure that random audits of these transactions are carried out to confirm that they are in compliance with the agreements, policies, or conditions established.

Future Trends in Related Party Transactions

In the case of related party transactions or transactions involving related parties, the Company operates according to the following principles:

  1. The Company will comply with its policies, the Securities and Exchange Act, regulations, announcements, orders, or requirements set by the Stock Exchange of Thailand, the Securities and Exchange Commission, and/or the Capital Market Supervisory Board. The Company will also adhere to disclosure requirements for related party transactions of the Company or its subsidiaries, in accordance with accounting standards set by the Federation of Accounting Professions and other relevant guidelines. These transactions will not involve the shifting or transfer of benefits between the company or its shareholders but will be conducted with the primary consideration of maximizing the benefits for the company and all of its shareholders.

  2. In cases where the transactions are regular or support normal business operations and are expected to continue in the future, the company will conduct them based on general trade practices. This includes referring to appropriate and fair prices and terms that are reasonable, verifiable, and aligned with standard commercial agreements approved by the Board of Directors. In this regard, management will prepare a summary of these transactions to report to the Audit Committee each quarter and for inclusion in the Annual Information Form/Annual Report (Form 56-1 One Report).

  3. Disclosure of related party transactions or transactions involving related parties will be in compliance with the laws and regulations set by the Securities and Exchange Commission and the Stock Exchange of Thailand, as well as accounting standards related to the company or related parties as prescribed by the Federation of Accounting Professions.

Contents